Skip to main content
Top

Open Access 26-04-2024 | Gastric Cancer | Original Article

Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives

Authors: S. C. Sodergren, A. Hurley-Wallace, V. Vassiliou, B. Alkhaffaf, B. Batsaikhan, A. S. Darlington, T. Fleitas-Kanonnikof, M. G. Guren, M. Honda, Y. W. Kim, S. Kim, M. N. Krishnamurthy, S. Y. Loh, N. S. Turhal, J. Zhou, K. Dennis, R. Krishnatry, M. Terashima, G. Tsironis, T. Yoshikawa, M. Terada, On behalf of the EORTC Quality of Life Group

Published in: Gastric Cancer

Login to get access

Abstract

Background

The EORTC QLQ-STO22 (QLQ-STO22) is a firmly established and validated measure of health-related quality of life (HRQoL) for people with gastric cancer (GC), developed over two decades ago. Since then there have been dramatic changes in treatment options for GC. Also, East Asian patients were not involved in the development of QLQ-STO22, where GC is most prevalent and the QLQ-STO22 is widely used. A review with appropriate updating of the measure was planned. This study aims to capture HRQoL issues associated with new treatments and the perspectives of patients and health care professionals (HCPs) from different cultural backgrounds, including East Asia.

Methods

A systematic literature review and open-ended interviews were preformed to identify potential new HRQoL issues relating to GC. This was followed by structured interviews where HCPs and patients reviewed the QLQ-STO22 alongside new issues regarding relevance, importance, and acceptability.

Results

The review of 267 publications and interviews with 104 patients and 18 HCPs (48 and 9 from East Asia, respectively) generated a list of 58 new issues. Three of these relating to eating small amounts, flatulence, and neuropathy were recommended for inclusion in an updated version of the QLQ-STO22 and covered by five additional questions.

Conclusions

This study supports the content validity of the QLQ-STO22, suggesting its continued relevance to patients with GC, including those from East Asia. The updated version with additional questions and linguistic changes will enhance its specificity, but further testing is required.
Appendix
Available only for authorised users
Literature
6.
go back to reference Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.CrossRefPubMed Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://​doi.​org/​10.​1016/​S0140-6736(10)61121-X.CrossRefPubMed
9.
go back to reference Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5.CrossRefPubMed Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71. https://​doi.​org/​10.​1016/​S0140-6736(17)31827-5.CrossRefPubMed
15.
go back to reference Wheelwright S, Bjordal K, Bottomley A, Gilbert A, Martinelli F, Pe M, et al. EORTC Quality of Life Group guidelines for developing questionnaire modules. 5th ed. Brussels: Belgium; 2021. Wheelwright S, Bjordal K, Bottomley A, Gilbert A, Martinelli F, Pe M, et al. EORTC Quality of Life Group guidelines for developing questionnaire modules. 5th ed. Brussels: Belgium; 2021.
Metadata
Title
Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives
Authors
S. C. Sodergren
A. Hurley-Wallace
V. Vassiliou
B. Alkhaffaf
B. Batsaikhan
A. S. Darlington
T. Fleitas-Kanonnikof
M. G. Guren
M. Honda
Y. W. Kim
S. Kim
M. N. Krishnamurthy
S. Y. Loh
N. S. Turhal
J. Zhou
K. Dennis
R. Krishnatry
M. Terashima
G. Tsironis
T. Yoshikawa
M. Terada
On behalf of the EORTC Quality of Life Group
Publication date
26-04-2024
Publisher
Springer Nature Singapore
Published in
Gastric Cancer
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-024-01492-8
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.